Related Experiment Videos
Prevention of heart failure.
1Cardiovascular Division, University of Minnesota Medical School, Minneapolis 55455, USA.
Cardiology
|February 1, 2000
Summary
Preventing heart failure (HF) progression is key. Early treatment of asymptomatic left ventricular dysfunction (LVD) with beta-blockers may reverse remodelling, but their efficacy versus ACE inhibitors requires further study.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure (HF) is progressive, necessitating early intervention to prevent worsening.
- Asymptomatic left ventricular dysfunction (LVD) requires treatment to preserve quality of life and exercise capacity.
- Left ventricular remodelling and dilatation must be prevented to halt clinical progression.
Purpose of the Study:
- To evaluate the comparative efficacy of beta-blocking agents and ACE inhibitors in preventing HF progression.
- To determine the impact of beta-blockers on left ventricular remodelling and dimensions.
- To investigate the combined effect of carvedilol and enalapril versus monotherapy in mild HF.
Main Methods:
- The CARMEN trial is a double-blind, randomized, parallel-group study.
- It involves 450 patients diagnosed with mild heart failure.
- Patients will be treated with carvedilol, enalapril, or a combination of both.
Main Results:
- Previous trials show ACE inhibitors reduce HF development but not mortality.
- Beta-blockers have demonstrated improvements in left ventricular ejection fraction and dimensions in HF patients.
- The relative efficacy of beta-blockers versus ACE inhibitors in remodelling regression is currently unknown.
Conclusions:
- Inhibition of the sympathetic nervous system via beta-blockers is a logical approach for HF and LVD.
- The CARMEN study aims to elucidate the comparative benefits of carvedilol and enalapril in mild HF.
- Understanding these treatment effects is crucial for optimizing HF management and preventing adverse remodeling.